What is GenScript ProBio?
GenScript ProBio operates within the dynamic Research & Development industry, headquartered in Piscataway, New Jersey. With a workforce ranging from 1000 to 4999 employees and an estimated revenue between $50 million and $100 million, the company is a notable player. Its focus on R&D suggests a commitment to innovation and the advancement of scientific discovery, positioning it to capitalize on emerging trends and opportunities within its specialized field.
How much funding has GenScript ProBio raised?
GenScript ProBio has raised a total of $220M across 1 funding round:
Series C
$220M
Series C (2023): $220M with participation from Legend Capital
Key Investors in GenScript ProBio
Legend Capital
Legend Capital is a prominent private equity fund manager with a focus on innovation and growth enterprises, particularly those with operations in or related to China. They manage substantial USD and RMB funds, indicating a broad investment scope.
What's next for GenScript ProBio?
The recent major strategic investment signals a pivotal phase for GenScript ProBio, likely indicating a move towards scaling operations, expanding market reach, or further developing its proprietary technologies. This substantial backing from investors suggests confidence in the company's business model and future prospects. GenScript ProBio is poised to leverage this capital for strategic growth, potentially exploring new partnerships, enhancing its product pipeline, and solidifying its competitive advantage in the R&D landscape.
See full GenScript ProBio company page
